Paul Perreault, CSL CEO
M&A season starts early? CSL seals $11.7B acquisition of Vifor Pharma
Australia’s CSL is plopping down $11.7 billion to acquire Vifor Pharma, the Swiss biotech best known for its iron products and kidney drugs.
While the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
